12:06:18 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-13 Bokslutskommuniké 2024
2024-11-06 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-07 Kvartalsrapport 2024-Q1
2024-04-25 Ordinarie utdelning ULTI 0.00 NOK
2024-04-24 Årsstämma 2024
2024-02-14 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-22 Kvartalsrapport 2023-Q2
2023-05-10 Kvartalsrapport 2023-Q1
2023-04-21 Ordinarie utdelning ULTI 0.00 NOK
2023-04-20 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-12 Kvartalsrapport 2022-Q1
2022-04-21 Ordinarie utdelning ULTI 0.00 NOK
2022-04-20 Årsstämma 2022
2022-02-17 Bokslutskommuniké 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-11 Kvartalsrapport 2021-Q1
2021-04-22 Ordinarie utdelning ULTI 0.00 NOK
2021-04-21 Årsstämma 2021
2021-02-17 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-11-11 Extra Bolagsstämma 2020
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-14 Kvartalsrapport 2020-Q1
2020-04-16 Ordinarie utdelning ULTI 0.00 NOK
2020-04-15 Årsstämma 2020
2020-02-14 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Ultimovacs är ett norskt läkemedelsbolag. Bolagets affärsinriktning är att utveckla immunoterapier mot diverse cancertillstånd. Forskning och utveckling utgår ifrån egenbaserad teknologisk plattform, där produkterna huvudsakligen vidareutvecklas som vaccin. Störst närvaro återfinns inom Europa och Nordamerika. Bolaget grundades under 2011 och har sitt huvudkontor i Oslo, Norge.
2020-05-14 08:00:00
Oslo, 14 May 2020: Ultimovacs ASA ("Ultimovacs", ticker ULTIMO), a
pharmaceutical company developing novel immunotherapies against cancer,
announces its first quarter 2020 results today. A presentation by the company's
management team will take place today on a webcast at 09:00 CET. The new CEO,
Carlos de Sousa, who will join Ultimovacs on 1 June 2020, will give an
introduction of himself during the presentation.

The presentation can be followed as a live webcast (access through the link
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20200514_4) which will
also be available on our website. 

Highlights for the first quarter of 2020:

o Despite the temporary halt in clinical trial activities at several hospitals
caused by the covid-19 situation, the first site in the INITIUM trial has
recently opened for patient inclusion. In total, an opening of 35-40 sites are
planned for this trial. Several additional sites are expected to open in Norway
and the US during Q2-20. The INITIUM trial is a randomized phase II trial for
investigation of UV1 as treatment for first-line patients with metastatic
malignant melanoma.

o Similarly, the first out of totally six planned sites in the NIPU trial has
also opened for patient inclusion. The NIPU trial is a randomized, multi-center
phase II trial where UV1 is investigated as second-line treatment in
mesothelioma.

o In the US based phase I trial in malignant melanoma, in which UV1 is given in
combination with a PD-1 checkpoint inhibitor, 8 of the planned 10 patients in
cohort 2 (dose finding GM-CSF) have been included as per the reporting date of
the Q1-20 report. Four of these patients have been included in the period of
covid-19 related lockdown in the US. No unexpected safety issues have been
observed to date.

o Total operating expenses amounted to MNOK 31.3 in Q1-20. Negative cash flow
from operations was MNOK 32.4 in Q1-20. Total cash and cash equivalents was
reduced by MNOK 31.5 during Q1-20, amounting to MNOK 367.7 as per 31 March 2020.

The report and presentation are also available on the company website. 


For further information, please see www.ultimovacs.com or contact:


Øyvind Kongstun Arnesen, CEO
oeyvind.arnesen@ultimovacs.com, +47 469 33810


Hans Vassgård Eid, CFO
hans.eid@ultimovacs.com, +47 482 48632